Twelve-month outcomes of ranibizumab versus aflibercept for macular oedema in branch retinal vein occlusion: data from the FRB! registry.

Adrian Robert Hunt Vuong NguyenCatherine P Creuzot-GarcherSocorro AlforjaPierre Henri Gabrielle Javier Zarranz-Ventura Martin Guillemin Samantha Fraser-BellRicardo P Casaroli MaranoJennifer ArnoldIan L McAllister Louise O'TooleMark C GilliesDaniel BarthelmesHemal Mehta

Published in: The British journal of ophthalmology (2021)

Visual outcomes at 12 months in this direct comparison of ranibizumab and aflibercept for BRVO in real-world practice were generally good and similar for the 2 drugs, despite a greater effect of aflibercept on CST and time to first grading of inactivity.

Keyphrases

age related macular degeneration
diabetic retinopathy
optical coherence tomography

healthcare
primary care

electronic health record
big data

type diabetes
glycemic control